Skip to content

Orphan Drugs: New Report Supports Investment For Pharma

April 26, 2013

The topic of a new model of orphan drugs for Big Pharma and its profitability is the main Internet Buzz during the Summer of 2012, when Thomson Reuters publishes an article titled, “The New Blockbusters: Orphan Drugs”. Big Pharma’s new strategic model of orphan drugs and rare diseases starts to replace Big Pharma’s traditional blockbuster drug model. Prof. M. Ian Phillips, Director of the Center for Rare Disease Therapies at the Keck Graduate Institute of Applied Life Sciences in California, writes an Editorial in the January 2013 issue of Expert Opinion on Orphan Drugs on this topic.

EvaluatePharma publishes in April 2013, the “Orphan Drug Report 2013”. EvaluatePharma provides life science sector analysis, “consensus forecasts, and trusted commercial insight into biotech and pharmaceutical performance.” The Report analyzes the orphan drug market between now and 2018 and provides detailed analysis and data. Some interesting statistics provided by the report on the global orphan drug market :

•   Worldwide orphan drug market to grow to $127 billion by 2018, a Compound Annual Growth Rate (CAGR) of 7.4%
•   Orphan drugs to be 15.9% of Worldwide prescription sales by 2018 (excluding generics)
•   Orphan drugs offer a greater Return On Investment (ROI), 1.7 times greater than the ROI for non-orphan drugs
•   In 2012, FDA orphan drug designations decrease 7%, EU orphan designations increase 44%, & Japan’s orphan designations increase 33%
•   Rituxan (Rituximab), from Roche, is the #1 global selling orphan drug in 2018
•   18.5% of EU orphan drug designations are for ultra-rare diseases
•   The top 5 indications in the EU with the most filed orphan drug designations:  Acute Myeloid Leukemia (AML – 45), Non-Hodgkin Lymphoma (NHL – 38), Glioma (37), Pancreatic cancer (35), and Cystic Fibrosis (35).

Please Note: “Azt” by John Crawford (Photographer) [Public domain] | Wikimedia Commons.

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: